

Date: 1 May 2019

**Re: Freedom of Information Request**  
**Ref: 97- 2019**

Thank you for your email dated 9th April 2019 requesting information in relation to patient treatments and drugs used.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

1 – Within your Health Trust how many patients are currently (within the past 3 months - 20<sup>th</sup> January 2019 to 19<sup>th</sup> April 2019) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC); If you do not treat, where do you refer these patients?

Axinitib = Exempt under S.40 Personal Information  
Cabozantinib = 22 patients  
Everolimus = Exempt under S.40 Personal Information  
Levatinib + Everolimus = 0 patients  
Nivolumab = 30 patients  
Nivolumab + Ipilimumab = 12 patients  
Pazopanib = 10 patients  
Sunitinib = 11 patients  
Temsirolimus = 0 patients  
Tivozanib = 24 patients

2 – Within your Health Trust how many patients are currently (within the past 3 months - 20<sup>th</sup> January 2019 to 19<sup>th</sup> April 2019) being treated with the following treatments for Melanoma?

If you do not treat, where do you refer these patients?

Bevacizumab = 0 patients  
Dabrafenib = Exempt under S.40 Personal Information  
Dabrafenib + Trametinib = 27 patients  
Dacarbazine (DTIC) = 0 patients  
Densoumab = 0 patients  
Encorafenib with Binimetinib = 0 patients  
Ipilimumab = Exempt under S.40 Personal Information  
Nivolumab = 37 patients  
Nivolumab + Ipilimumab = 13 patients  
Pembrolizumab = 0 patients however we have treated 60 patients with Pembrolizumab  
Trametinib = Exempt under S.40 Personal Information  
Vemurafenib = 0 patients  
Vemurafenib + Cobimetinib = 0 patients

2a – In the past 3 months, how many Melanoma patients were BRAF+? (Based on patients with a diagnosis date between 1<sup>st</sup> Oct 18 and 31<sup>st</sup> Dec 18)

We only record BRAF status for skin melanoma patients. For the 15 skin melanoma patients diagnosed in our timeframe 2 patients were BRAF V600 positive, 8 were BRAF V600 negative and the remaining 5 we do not have the BRAF V600 status recorded

3 – Within your Health Trust how many patients are currently (within the past 3 months - 20<sup>th</sup> January 2019 to 19<sup>th</sup> April 2019) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC); If you do not treat, where do you refer these patients?

Bevacizumab = 0 patients  
Cisplatin = 0 patients however we have treated 13 patients with Cisplatin + Gemcitabine  
Doxorubicin = 0 patients  
Everolimus = 0 patients  
Lapatinib = 0 patients  
Lenvantinib = 6 patients  
Sorafenib = 16 patients  
Sunitinib = 0 patients

4 – Within your Health Trust how many patients are currently (within the past 3 months - 20<sup>th</sup> January 2019 to 19<sup>th</sup> April 2019) being treated with the

**following treatments for Thyroid Cancer; if you do not treat, where do you refer these patients?**

**Axitinib = 0 patients**

**Cabozantinib = Exempt under S.40 Personal Information**

**Lenvantinib = Exempt under S.40 Personal Information**

**Pazopanib = 0 patients**

**Sorafenib = Exempt under S.40 Personal Information**

**Sunitinib = 0 patients**

**Vandetanib = 0 patients**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**